D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Investing.com - William Blair initiated coverage on Dianthus Therapeutics (NASDAQ:DNTH) with an Outperform rating and set a fair value of $47.57 per share. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $34 to $84.
The research firm identified Dianthus as a clinical-stage biotechnology company focused on developing DNTH103, an active C1s monoclonal antibody.
William Blair noted that DNTH103 is being developed specifically for autoimmune neuromuscular indications, representing the company’s primary therapeutic focus.
The analyst assessment highlighted that risks associated with an investment in Dianthus are primarily clinical, regulatory, and commercial in nature.
These investment risks were characterized as similar to those typically found with other biotechnology companies, according to William Blair’s research note.
In other recent news, Dianthus Therapeutics has completed patient enrollment for its Phase 2 MaGic trial, which is evaluating the efficacy of DNTH103 in individuals with generalized Myasthenia Gravis. The trial recruited 65 participants, surpassing its target of 60, and is designed to assess the safety and tolerability of the drug, with results expected in September 2025. Stifel has reiterated a buy rating and a $52.00 price target for Dianthus Therapeutics, following discussions with the company’s leadership about the potential of DNTH103. The drug is also being studied in other conditions, such as Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy, with results anticipated in 2026. Additionally, Dianthus Therapeutics announced the appointment of Dr. Simon Read to its Board of Directors, bringing over 30 years of industry experience to the company. Dr. Read expressed enthusiasm for the company’s progress with DNTH103 and its potential impact on severe neuromuscular conditions. The company also noted that Lonnie Moulder would be stepping down from the board. These developments are part of Dianthus Therapeutics’ ongoing efforts in antibody complement therapeutics for severe autoimmune diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.